Prior to a notable event, shares of FibroBiologics, Inc. (NASDAQ: FBLG) have experienced a remarkable upward trend, appreciating by 53.88% to close the previous trading session at $10.31. This surge reflects growing investor confidence and anticipation.
Upcoming Presentation At ECM Pharmacology Congress
FibroBiologics (FBLG) has announced that Dr. Hamid Khoja, Chief Scientific Officer, will speak at the Extracellular Matrix (ECM) Pharmacology Congress in Copenhagen, Denmark on June 17–19, 2024, about the company’s wound care and psoriasis initiatives. Prominent specialists from different disciplines and generations can share their knowledge on how to modify the extracellular matrix in a range of clinical contexts at the ECM Pharmacology Congress.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
FibroBiologics will showcase their developments in using fibroblasts for extracellular matrix remodeling at this esteemed conference. These results demonstrate how fibroblast-derived medications have the potential to revolutionize the treatment of long-term illnesses including psoriasis and wound healing. With the goal of creating novel medications, FibroBiologics focuses on the immunomodulatory and regenerative properties of fibroblasts.
Collaboration With Charles River Laboratories
FibroBiologics and Charles River Laboratories, a well-known supplier of drug research, manufacturing, and discovery solutions worldwide, have announced a letter of intent, signifying a significant strategic move. In advance of an upcoming master services agreement, this arrangement enables the transfer, testing, and validation of FibroBiologics’ technology.
The goal of this partnership is to create and produce fibroblast-based spheroids, a master cell bank, and a functional cell bank for FibroBiologics’ clinical trials. The application of fibroblasts’ immunomodulatory and regenerative properties in the management of chronic illnesses is being investigated by FibroBiologics. Degenerative disc disease, multiple sclerosis, wound healing, psoriasis, thymic involution reversal, and cancer are among the illnesses being studied.
To help get these treatments closer to the clinic, FibroBiologics’ cell production technologies will be the subject of feasibility studies at Charles River Laboratories. Charles River would serve as the contract development and manufacturing organization (CDMO) to manufacture pharmaceutical items for some of FibroBiologics’ clinical studies, pending the completion of a master services agreement.
